In the present investigation, we found for the first time that Cerebrolysin® and donepezil induced a synergistic reduction in plasma NDE Aβ42, and that Cerebrolysin® and/or combination therapy reduced NDEV levels of total tau, P-T181-tau, and P-S396-tau with respect to donepezil monotherapy in mild to moderately severe AD patients. The gene discussed is MAPT; the disease is Alzheimer disease.